ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Every earnings call announcement on NSE and BSE that our alert engine sent, newest first. Each one has its own page with the summary, the key figures and the original filing.
Time
9,412 announcements
Q2 revenue +45% and PAT +55% on a low base, with debt cut to ₹646 Cr. Kanjurmark conversion timing is unresolved with no cost estimate, Versova sales are stalled, and management deflected on cost pressure.
Ambuja Cements (filed by ACC) Q2 FY27: consol revenue ₹9,197 Cr, EBITDA ₹1,271 Cr (~14%), PAT ₹236 Cr; volumes flattish, capex stepped up.
Q2 FY27 revenue Rs 311 Mn, adj. EBITDA Rs (88) Mn, PAT Rs (107) Mn; H1 revenue Rs 701 Mn, PAT Rs (246) Mn. Pivot toward lifestyle and non-lounge services.
H1 FY27 (Apr–Sep 2026): revenue ₹7,724.7 lakh (+44.4% YoY), EBITDA ₹1,551.8 lakh (20.1% margin), PAT ₹935.3 lakh (+52.2%, 12.1% margin). Growth is strong, but operating cash flow is negative on working-capital build.
Record H1 profit: PAT ₹866 Cr (+108%) on revenue ₹4,570 Cr (+14%); Q2 revenue fell to ₹2,213 Cr from ₹2,294 Cr, profit growth driven by margins.
Record ₹385 Cr disbursements and 16% AUM growth, but SME retail stalled and gross NPA rose to 1.13% from 0.95%. PAT grew only 2% YoY, largely due to a low tax base.
Revenue rose 19% to ₹1,045 Cr and PAT was about 5x, but operating EBITDA was flat at an 8.4% margin as ad spend and raw-material costs absorbed gross margin. Growth is price-led with flat volumes, and the Furlenko consolidation flatters the forward story.
Q2 FY27 consolidated sales Rs826 Cr (+13.3%), EBITDA Rs189 Cr (+43.2%), PAT Rs94 Cr (+23.7%) after Rs22 Cr German closure exceptional; net cash Rs3,827 Cr.
Q2 FY27 improved year-on-year but margins fell sequentially on product realisation, coal costs and wage provisions. Management declined to comment on Q3 or October trends.
Volumes grew about 8% and daily sales hit a record 10.06 MMSCMD, but costly spot LNG drove a negative EBITDA of about ₹31 Cr. Management stayed vague on margin recovery and offered no breakeven price.
Consolidated revenue ~₹4,108 Cr; lead acid up ~18%, new energy up 30%+. Margins fell ~1.3ppt to 8.8% on raw material inflation and new-energy spend. Management attributes the squeeze to costs, not demand.
Record consolidated revenue of ₹379 Cr (+33%) and PAT of ~₹70 Cr (+23%) at a 34.5% EBITDA margin. Growth was partly IPO-led, and regulatory and NBFC funding-cost risks were acknowledged but not quantified.
H1 FY27 revenue ₹2,505.37L (-5.3% YoY), EBITDA ₹540.27L (+34.1%), PAT ₹350.36L (+36.7%), EBITDA margin 21.56% (+633bps). Capacity expansion to 1,63,200 screens by March 2027.
Record Q2 turnover of ₹2,373 Cr and H1 volumes up 4.48%, but revenue growth was only 0.93% as tariff cuts bit. Management declined to update domestic FY27 guidance until December, citing Hormuz disruption.
Q2 FY27 revenue INR 767 Mn (+41.3% YoY), EBITDA margin 21.1%, PAT INR 113 Mn (+54.8%); H1 revenue +48.6%. Outcome-based AI adtech growth with international expansion.
Q2FY27 revenue INR 401 Cr (+40%), PAT INR 39 Cr (+30%). H1FY27 revenue INR 710 Cr (+41%), PAT INR 72 Cr (+53%). EBITDA margin eased to 19.0% from 21.7%.
Q2FY27 income Rs457.2 Cr (-11.4% YoY), PAT Rs51.1 Cr (-47.0%), EBITDA margin 22.9% on operating deleverage. H1FY27 income Rs1107.2 Cr (+35.6%), PAT Rs198.5 Cr (+80.2%). Capex-led R&D and peptide build-out.
Q2 FY27 revenue ₹347.92 Cr (+89.5% YoY) and PAT ₹33.68 Cr, but EBITDA margin fell ~300bps QoQ to ~21% on freight and energy costs; management reiterates 20%+ EBITDA only as an 'aspiration'.
Q2FY27 consolidated revenue Rs 95.5 Cr (+90% YoY), EBITDA loss narrowed to Rs 11.4 Cr from Rs 25.3 Cr, net loss Rs 22.3 Cr. Residences, Care Homes and AGEasy all scaling; management frames a path to profitability.
Q2 FY27 consolidated total income Rs 1561 Cr (+47.5%), PAT Rs 102 Cr (+27.3%), EBITDA margin 11.8% diluted by alloy pass-through. HPDC alloy wheel supply started.
Q2 FY27 revenue Rs440.1 Cr (+16.3% YoY), PAT Rs45.0 Cr (+23.6% YoY), EBITDA margin 18.6%. Growth from bushings, stampings and India engineering; Advantek turnaround and Romania downsizing.
Q2FY27 revenue ₹2,247 Mn (+54.9% YoY), EBITDA ₹292 Mn (13.0% margin), PAT ₹164 Mn (-11.7% YoY). Retail-led growth; Gujarat store rollout underway.
Q2 FY27 growth came from a Maldives recovery (~20%) and India (~10%), but reported PAT fell 47% on higher depreciation (₹79 Cr to ₹102 Cr).
Q2FY27 consolidated revenue ₹434 Cr (+36% YoY), EBITDA ₹45 Cr at 10.3% margin, PAT loss narrowed to ₹(6) Cr. Pharma led recovery; Crop Protection margins pressured.
Q2 FY27 revenue Rs4,915mn (+9.2% YoY), but EBITDA margin fell to 0.45% and PAT loss was Rs281mn. Rights issue up to Rs2,500mn approved.
Q2 revenue ₹1,146 Cr (+28% QoQ), but PAT only ₹69 Cr after a ₹32 Cr ECL charge. Order book ₹12,282 Cr. Execution targets now described as 'hopeful'.
Q2 FY27 revenue ₹18,272mn (+61% YoY, ~46% ex-Multilink). Reported EBITDA ₹2,618mn at 14.3% margin, down 330bps. Adjusted PAT ₹1,615mn (+30%).
Q2 FY27 revenue ₹204.53 Cr (+174.7% YoY) and PAT ₹9.26 Cr (+47.0%). H1 revenue ₹348.86 Cr already exceeds FY26 total. EBITDA margin compressed to 7.00%. Strategy: integrated MICE-plus-travel platform.
Q2 FY27: standalone income up 32% YoY to ₹305.4 Cr on bromine pricing; consolidated PAT only up 8%. H1 consolidated EBITDA down 5.2%; SOP guidance cut to 3.5–4k t, with fuel and PVC risks.
Consolidated revenue ₹1,342 Cr (+31.9% YoY) and EBITDA ₹195 Cr (+106%), led by CDMO volumes. Management gave no numeric guidance. API still loss-making and domestic branded growth is only about 8%.